-+ 0.00%
-+ 0.00%
-+ 0.00%

PERIOPERATIVE IMFINZI® (DURVALUMAB) PLUS NEOADJUVANT ENFORTUMAB VEDOTIN GRANTED PRIORITY REVIEW IN THE US FOR PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER

Reuters·09/25/2026 11:00:00

Please log in to view news